The novel CCK antagonist L364,718 abolished caerulein- but potentiates morphine-induced antinociception.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  European Journal of Pharmacology

• Publication date

  1988-07-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0014-2999(88)90849-7PMID 3208830
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: sensitisation by naloxone.

  1987cited by this paper
• Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists

  1987cited by this paper
• Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.

  1986cited by this paper
• Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates.

  1985cited by this paper
• Naloxone Potentiation of the Antinociceptive Action of Caerulein a

  1985cited by this paper
• Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia.

  1983cited by this paper
• A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS

  1980cited by this paper

• Effect of intracerebroventricular and systemic injections of caerulein, a CCK analogue, on electrical self-stimulation and its interaction with the CCKA receptor antagonist, L-364,718 (MK-329)

  2005influential citation
• Opioid Receptors: Targets for New Gastrointestinal Drug Development

  2000cites this paper
• EFFECTS OF CCK RECEPTOR AGONISTS AND ANTAGONISTS ON MORPHINE-INDUCED ANTINOCICEPTION IN MICE

  2000cites this paper
• Signal transduction in neuropathic pain, with special emphasis on the analgesic role of opioids - Part II: Moving basic science towards a new pharmacotherapy*

  1999cites this paper
• The Pharmacology of Pain

  1997cites this paper
• In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics.

  1997cites this paper
• Cholecystokinin-induced antinociception is not blocked by CCK-A or CCK-B receptor antagonists.

  1997cites this paper
• Novel Modulators in Nociception

  1997cites this paper
• Neurobiological Mechanisms of Opiate Withdrawal

  1996cites this paper
• The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance.

  1996cites this paper
• Neuropsychopharmacology of Opiate Dependence

  1996cites this paper
• Opioid and anti‐opioid peptides

  1995cites this paper
• Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.

  1994cites this paper
• Mu and delta opioid receptors mediate opposite modulations by morphine of the spinal release of cholecystokinin-like material.

  1994cites this paper
• Characterization of the effect of cholecystokinin (CCK) on neurons in the periaqueductal gray of the rat: immunocytochemical and in vivo and in vitro electrophysiological studies.

  1994cites this paper
• CCK peptides and mRNA in the human brain.

  1993cites this paper
• Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain

  1993cites this paper
• The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment.

  1992cites this paper
• Inhibitory effect of CCK-8 and ceruletide on glutamate-induced rises in intracellular free calcium concentrations in rat neuron cultures.

  1992cites this paper
• Activation of CCK-A receptors induces elevation of plasma corticosterone in rats.

  1992cites this paper
• Cholecystokinin octapeptide alters morphine-induced effects on EEG power spectra both quantitatively and qualitatively.

  1992cites this paper
• Influence of the selective cholecystokinin antagonist L-364,718 on pain threshold and morphine analgesia.

  1991cites this paper
• Cholecystokinin antagonists.

  1991cites this paper
• Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey.

  1990cites this paper
• The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat.

  1990cites this paper
• The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey.

  1990cites this paper
• Differential effects of the CCK antagonist, MK-329, on analgesia induced by morphine, social conflict (opioid) and defeat experience (non-opioid) in male mice.

  1989cites this paper
• The role of CCK, caerulein, and CCK antagonists in nociception

  1989cites this paper
• Caerulein-induced antinociception: interaction with morphine and opioid antagonists in the rat.

  1989cites this paper